Bruzzone, S. E. P.
Ozenne, B.
Fisher, P. M.
Ortega, G.
Jensen, P. S.
Dam, V. H.
Svarer, C.
Knudsen, G. M.
Lesch, K. P.
Frokjaer, V. G.
Funding for this research was provided by:
Horizon 2020 (953327, 953327, 953327, 953327)
Innovationsfonden (5189-00087A, 5189-00087A, 5189-00087A, 5189-00087A, 5189-00087A)
Lundbeck Foundation (R279-2018-1145, R279-2018-1145, R279-2018-1145, R279-2018-1145)
Research Council of Rigshospitalet (A6594)
Article History
Received: 19 January 2024
Accepted: 6 May 2024
First Online: 27 May 2024
Declarations
:
: All studies protocols comply with the Declaration of Helsinki. All participants provided written and informed consent before being included in the research studies. Data of healthy participants included in this study are from the Cimbi database (). All research projects generating the data included in the Cimbi database have been approved by the Danish Data Protection Agency and the local scientific ethics committee. Data of patients with major depressive disorder included in this study are from the NeuroPharm 1 study, a clinical trial registered at clinicaltrials.gov (NCT02869035) on 16 August 2016. The study protocol was approved by the Health Research Ethics Committees of the Capital Region of Denmark (reference number: H-15017713), the Danish Medicines Agency (protocol number: NeuroPharm-NP1, EudraCT-number 2016–001626-34) and the Danish Data Protection Agency (04711/RH-2016–163).
: Not applicable.
: The authors declare that they have no competing interests.